Sotatercept: A novel therapeutic approach for pulmonary arterial hypertension through transforming growth factor-β signaling modulation
Authors:
Open Access
- 20 September 2025
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Methodology
- Vol. 15 (3) , 102688
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease marked by degeneration of the lung’s blood vessels. As the disease progresses, the resistance to blood flow in the pulmonary arteries increases, putting a strain on the right side of the heart as it pumps blood through the lungs. PAH is characterized by changes in the structure of blood vessels and excessive cell growth. Untreated PAH leads to irreversible right-sided heart failure, often despite medical intervention. Patients experience a gradual decline in function until they are unable to perform daily activities. Advances in treatment have improved the prognosis for many PAH patients. Currently approved therapies target the prostacyclin, endothelin, nitric oxide, or phosphodiesterase pathways to slow the progression of the disease. To address the unmet need for effective PAH therapies, research efforts are focused on identifying new targets and developing therapies that specifically address the underlying disease mechanisms and restore vascular wall homeostasis. Among these, sotatercept, a fusion protein that targets the transforming growth factor-β superfamily signaling pathway, has emerged as a promising therapeutic option. In this review, we examine the available evidence from clinical trials to assess the potential of sotatercept as a treatment for PAH.Keywords
This publication has 21 references indexed in Scilit:
- Construction of homologous branched oligomer megamolecules based on linker-directed protein assemblySoft Matter, 2024
- Emerging pharmacotherapies for the treatment of pulmonary arterial hypertensionExpert Opinion on Investigational Drugs, 2023
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2023
- Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertensionScientific Reports, 2022
- Sotatercept for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2021
- Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial HypertensionJACC: Basic To Translational Science, 2020
- Management of Pulmonary Arterial HypertensionCurrent Cardiovascular Risk Reports, 2020
- Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion InjuryMolecular Therapy, 2019
- TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertensionDrug Discovery Today, 2019
- Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialThe Lancet Haematology, 2018